Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.50 |
| ▸ | CCR1 | P32246 | 3/20 | 0.44 |
| ▸ | CCR5 | P51681 | 3/20 | 0.44 |
| ▸ | CCR8 | P51685 | 3/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | METAP1 | P53582 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.42 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | ALPL | P05186 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | ALPI | P09923 | 1/20 | 0.42 |
| ▸ | ALPG | P10696 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4736973 | 0.82 | CCR1 (0.51) | ADORA2AADORA1CCR1CCR5CCR8 | |
| SCHEMBL4849634 | 0.80 | MAPT (0.45) | ADORA2AADORA1KDM4ELMNACYP1A2 | |
| SCHEMBL8140217 | 0.78 | ADORA2A (0.50) | ADORA2AADORA1CCR1CCR5CCR8 | |
| SCHEMBL4857319 | 0.77 | ADORA2A (0.38) | ADORA2AADORA1KDM4ESMN1; SMN2L3MBTL1 | |
| SCHEMBL4854161 | 0.77 | ADORA2B (0.36) | ADORA2AADORA1SMN1; SMN2RXFP1RAB9A | |
| SCHEMBL577738 | 0.76 | ADORA2A (0.53) | ADORA2AADORA1SLC2A1KDM4EMETAP1 | |
| SCHEMBL4855822 | 0.75 | MPL (0.43) | ADORA2AADORA1HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL10610977 | 0.74 | KDM4E (0.57) | KDM4EMETAP1LMNAMAPK1SMN1; SMN2 | |
| SCHEMBL10292789 | 0.71 | KDM4E (0.52) | ADORA2AADORA1CCR1CCR5CCR8 | |
| SCHEMBL27916951 | 0.71 | AXL (0.38) | ADORA2AADORA1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371752-B2 | Aryl fused substituted 4-oxy-pyridines | NEUROGEN CORPORATION (US) | 2008-05-13 | — | — | US | claimed |
| US-20050154008-A1 | Aryl fused substituted 4-oxy-pyridines | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-07-14 | — | — | US | claimed |
| US-20020035121-A1 | Aryl fused substituted 4-oxy-pyridines | CAI GUOLIN (US) | 2002-03-21 | — | — | US | claimed |
| US-8211897-B2 | Inhibitors of cathepsin B | VIROBAY, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211897-B2 | Inhibitors of cathepsin B | VIROBAY, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| WO-2009100225-A1 | INHIBITORS OF CATHEPSIN B | VIROBAY, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090203629-A1 | INHIBITORS OF CATHEPSIN B | VIROBAY, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090203629-A1 | INHIBITORS OF CATHEPSIN B | VIROBAY, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| WO-2008086053-A1 | HCV INHIBITORS | VIROBAY, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008086053-A1 | HCV INHIBITORS | VIROBAY, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| US-20080161254-A1 | HCV INHIBITORS | VIROBAY, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20070249637-A1 | Inhibitors Of Hepatitis C Virus Protease, And Compositions And Treatments Using The Same | COLLINS MICHAEL R | 2007-10-25 | — | — | US | disclosed |
| US-20070249637-A1 | Inhibitors Of Hepatitis C Virus Protease, And Compositions And Treatments Using The Same | COLLINS MICHAEL R | 2007-10-25 | — | — | US | disclosed |
| US-20070249637-A1 | Inhibitors Of Hepatitis C Virus Protease, And Compositions And Treatments Using The Same | COLLINS MICHAEL R | 2007-10-25 | — | — | US | disclosed |
| EP-1805187-A1 | INHIBITORS OF HEPATITIS C VIRUS PROTEASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | Pfizer, Inc. (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006043145-A1 | INHIBITORS OF HEPATITIS C VIRUS PROTEASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| WO-2006043145-A1 | INHIBITORS OF HEPATITIS C VIRUS PROTEASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20050154008-A1 | Aryl fused substituted 4-oxy-pyridines | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-07-14 | — | — | US | disclosed |
| US-6828329-B2 | Agonists, antagonists for gamma-aminobutyric acid brain receptors useful in diagnosis and treatment of anxiety depressionm, down syndrome, sleep and seizure disorders | NEUROGEN CORPORATION | 2004-12-07 | — | — | US | disclosed |
| US-20020035121-A1 | Aryl fused substituted 4-oxy-pyridines | CAI GUOLIN (US) | 2002-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161254-A1 | HCV INHIBITORS | HAVCR2, ZC3HAV1, EIF2AK2 | ADORA2A 3228/4885ADORA1 2845/4885CCR1 699/4885 |
| US-20050154008-A1 | Aryl fused substituted 4-oxy-pyridines | CHRNA7, CHRNA4, GABRA6 | ADORA2A 81/4885ADORA1 109/4885CCR1 2117/4885 |
| US-20020035121-A1 | Aryl fused substituted 4-oxy-pyridines | GABRA4, GABRA6, GABRG2 | ADORA2A 73/4885ADORA1 80/4885CCR1 2027/4885 |
| US-20070249637-A1 | Inhibitors Of Hepatitis C Virus Protease, And Compositions And Treatments Using The Same | SERPINB1, CTSC, CTSV | ADORA2A 4505/4885ADORA1 3990/4885CCR1 464/4885 |
| US-20090203629-A1 | INHIBITORS OF CATHEPSIN B | CTSB, CSTB, CTSF | ADORA2A 2613/4885ADORA1 1664/4885CCR1 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.